Research graph
References from In vivo CAR T-cell generation: delivery platforms, clinical progress, and translational barriers. Local targets link to admitted publications; unresolved targets remain external evidence.
From concept to cure: The evolution of CAR-T cell therapy
10.1016/j.ymthe.2025.03.005 · 2025 · External reference
Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial
10.1016/j.eclinm.2025.103229 · 2025 · External reference
Decoding signaling architectures: CAR versus TCR dynamics in solid tumor immunotherapy
10.3724/abbs.2025190 · 2026 · External reference
Exploring T cell receptor repertoires in myocardial diseases
10.1161/circresaha.124.323661 · 2024 · External reference
CAR-T cell therapy for acute myeloid leukemia: Preclinical rationale, current clinical progress, and barriers to success
10.1007/s40259-021-00477-8 · 2021 · External reference
CAR-T cell manufacturing: Major process parameters and next-generation strategies
10.1084/jem.20230903 · 2024 · External reference
Cancer cell therapies: Global clinical trial trends and emerging directions
10.1038/d41573-025-00180-1 · 2025 · External reference
The precision revolution in hematologic Malignancies: A decade of transformative immunotherapies and targeted agents
10.3390/jcm14248896 · 2025 · External reference
CAR-M therapy in the era of tumor immunotherapy: Current research progress and engineering strategies
10.3389/fimmu.2025.1723270 · 2025 · External reference
Lyophilized lymph nodes for improved delivery of chimeric antigen receptor T cells
10.1038/s41563-024-01825-z · 2024 · External reference
In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy
10.3389/fonc.2022.809754 · 2022 · External reference
Cytokines in CAR T cell-associated neurotoxicity
10.3389/fimmu.2020.577027 · 2020 · External reference
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
10.1056/nejmoa1707447 · 2017 · External reference
CAR T cell immunotherapy for human cancer
10.1126/science.aar6711 · 2018 · External reference
Living therapeutics of nonpathogenic bacteria as biosynthesis factory and active carriers for enhancing tumor-targeted therapy
10.1038/s41467-025-61675-4 · 2025 · External reference
Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung
10.1038/s41467-024-55751-4 · 2025 · External reference
Next-generation immune profiling - beyond blood cancer cells
10.1016/j.molmed.2025.06.004 · 2025 · External reference
In vivo CAR T cells move into clinical trials
10.1038/d41573-024-00150-z · 2024 · External reference
Soluble factors released by peripheral blood-derived CAR-NK cells cause bystander myeloid cell activation
10.3389/fimmu.2024.1519415 · 2024 · External reference
Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors
10.1038/leu.2016.180 · 2017 · External reference
IFN-γ-mediated suppression of Caspase-7 exacerbates acute lung injury induced by CAR-T cells
10.1016/j.ymthe.2025.03.023 · 2025 · External reference
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
10.1016/s0140-6736(25)01030-x · 2025 · External reference
In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus
10.1056/nejmc2509522 · 2025 · External reference
Engineered T cells: The promise and challenges of cancer immunotherapy
10.1038/nrc.2016.97 · 2016 · External reference
Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions
10.1016/0006-291x(87)90502-x · 1987 · External reference
CAR-T design: Elements and their synergistic function
10.1016/j.ebiom.2020.102931 · 2020 · External reference
Redirecting mouse CTL against colon carcinoma: Superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma
10.4049/jimmunol.166.1.182 · 2001 · External reference
The principles of engineering immune cells to treat cancer
10.1016/j.cell.2017.01.016 · 2017 · External reference
Recent advances in CAR-T cell engineering
10.1186/s13045-020-00910-5 · 2020 · External reference
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells
10.1038/s41591-021-01326-5 · 2021 · External reference
4-1BB signaling beyond T cells
10.1038/cmi.2010.82 · 2011 · External reference
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
10.1172/jci.insight.96976 · 2018 · External reference
Chimeric antigen receptor T cell therapy targeting CD19-positive leukemia and lymphoma in the context of stem cell transplantation
10.1089/hum.2016.097 · 2016 · External reference
TRUCKs: The fourth generation of CARs
10.1517/14712598.2015.1046430 · 2015 · External reference
Harnessing the potential of CAR-T cell therapy: Progress, challenges, and future directions in hematological and solid tumor treatments
10.1186/s12967-023-04292-3 · 2023 · External reference
Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development
10.1016/j.ymthe.2023.09.021 · 2023 · External reference
A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects
10.1038/nm.4478 · 2018 · External reference
Teaching an old dog new tricks: Next-generation CAR T cells
10.1038/s41416-018-0325-1 · 2019 · External reference
The journey of CAR-T therapy in hematological Malignancies
10.1186/s12943-022-01663-0 · 2022 · External reference
Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases
10.1186/s40364-025-00736-8 · 2025 · External reference
The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases
10.1016/j.medj.2024.03.016 · 2024 · External reference
Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts
10.15252/emmm.201607485 · 2017 · External reference
Clinical manufacturing of CAR T cells: Foundation of a promising therapy
10.1038/mto.2016.15 · 2016 · External reference
High cost of chimeric antigen receptor T-cells: Challenges and solutions
10.1200/edbk_397912 · 2023 · External reference
The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects
10.1016/j.drudis.2021.04.020 · 2021 · External reference
In vivo CAR-T cell engineering: Concept, research progress, potential challenges and enhancement strategies
10.1186/s40164-025-00725-5 · 2025 · External reference
In situ programming of CAR-T cells: A pressing need in modern immunotherapy
10.1007/s00005-023-00683-y · 2023 · External reference
In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy
10.1186/s13045-024-01633-7 · 2024 · External reference
Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms
10.1016/j.ymthe.2022.05.018 · 2022 · External reference
Clinical use of lentiviral vectors
10.1038/s41375-018-0106-0 · 2018 · External reference
Viral vector platforms within the gene therapy landscape
10.1038/s41392-021-00487-6 · 2021 · External reference
Direct in vivo CAR T cell engineering
10.1016/j.tips.2024.03.004 · 2024 · External reference
Clinical technology advances driving in vivo CAR therapy
10.1016/j.tibtech.2025.11.006 · 2026 · External reference
Differences in the phenotypes and transcriptomic signatures of chimeric antigen receptor T lymphocytes manufactured via electroporation or lentiviral transfection
10.3389/fimmu.2023.1068625 · 2023 · External reference
CAR gene delivery by T-cell targeted lentiviral vectors is enhanced by rapamycin induced reduction of antiviral mechanisms
10.1002/advs.202302992 · 2023 · External reference
From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors
10.3389/fimmu.2025.1626369 · 2025 · External reference
Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector
10.1016/j.ymthe.2025.07.006 · 2025 · External reference
Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors
10.1182/bloodadvances.2020002229 · 2020 · External reference
Highly efficient and selective CAR-gene transfer using CD4- and CD8-targeted lentiviral vectors
10.1016/j.omtm.2019.03.003 · 2019 · External reference
Exclusive transduction of human CD4+ T cells upon systemic delivery of CD4-targeted lentiviral vectors
10.4049/jimmunol.1500956 · 2015 · External reference
Surface-engineered lentiviral vectors for selective gene transfer into subtypes of lymphocytes
10.1016/j.omtm.2018.10.006 · 2019 · External reference
Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering
10.1136/jitc-2022-006292 · 2023 · External reference
In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand
10.1182/blood.2024024523 · 2024 · External reference
From ex vivo to in vivo: advances in lentiviral vector engineering for CAR-T therapy
10.4110/in.2026.26.e13 · 2026 · External reference
Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation
10.1016/j.ymthe.2025.06.036 · 2025 · External reference
Viral vectors for gene transfer
10.1002/cpmo.58 · 2018 · External reference
Adenovirus-associated defective virus particles
10.1126/science.149.3685.754 · 1965 · External reference
Immunogenicity and toxicity of AAV gene therapy
10.3389/fimmu.2022.975803 · 2022 · External reference
AAV vector immunogenicity in humans: a long journey to successful gene transfer
10.1016/j.ymthe.2019.12.010 · 2020 · External reference
AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia
10.1038/s41408-021-00508-1 · 2021 · External reference
CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53
10.1056/nejmoa2411507 · 2025 · External reference
A guide to approaching regulatory considerations for lentiviral-mediated gene therapies
10.1089/hgtb.2017.096 · 2017 · External reference
Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers
10.1038/s41467-017-00505-8 · 2017 · External reference
Tools for translation: non-viral materials for therapeutic mRNA delivery
10.1038/natrevmats.2017.56 · 2017 · External reference
Polymer- and lipid-based gene delivery technology for CAR T cell therapy
10.1016/j.jconrel.2022.11.038 · 2023 · External reference
The 60-year evolution of lipid nanoparticles for nucleic acid delivery
10.1038/s41573-024-00977-6 · 2024 · External reference
A guide to manufacturing CAR T cell therapies
10.1016/j.copbio.2018.01.025 · 2018 · External reference
Nanoparticles for nucleic acid delivery: applications in cancer immunotherapy
10.1016/j.canlet.2019.04.040 · 2019 · External reference
Cationic polymers for non-viral gene delivery to human T cells
10.1016/j.jconrel.2018.02.043 · 2018 · External reference
Tuning lipid nanoparticles for RNA delivery to extrahepatic organs
10.1002/adma.202401445 · 2024 · External reference
Liposome composition in drug delivery design, synthesis, characterization, and clinical application
10.1016/j.addr.2021.113851 · 2021 · External reference
Biomaterials promote in vivo generation and immunotherapy of CAR-T cells
10.3389/fimmu.2023.1165576 · 2023 · External reference
CAR T cells produced in vivo to treat cardiac injury
10.1126/science.abm0594 · 2022 · External reference
In situ engineering of mRNA-CAR T cells using spleen-targeted ionizable lipid nanoparticles to eliminate cancer cells
10.1016/j.nantod.2024.102518 · 2024 · External reference
Precise in vivo RNA base editing with a wobble-enhanced circular CLUSTER guide RNA
10.1038/s41587-024-02313-0 · 2025 · External reference
Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting
10.1016/j.xcrm.2025.102250 · 2025 · External reference
T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles
10.1136/jitc-2025-011759 · 2025 · External reference
Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis
10.1056/nejmoa1716153 · 2018 · External reference
In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo
10.1038/s41467-020-19486-2 · 2020 · External reference
Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological Malignancies
10.1016/j.ymthe.2026.02.020 · 2026 · External reference
ApoE2-DARPin fusion proteins enable selective RNA transfer to CD8 T cells by lipid nanoparticles
10.1016/j.jconrel.2025.114377 · 2025 · External reference
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
10.1038/nnano.2017.57 · 2017 · External reference
In vivo delivery processes and development strategies of lipid nanoparticles
10.1002/cbic.202400481 · 2024 · External reference
Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles
10.1038/mtna.2013.66 · 2013 · External reference
Balancing multivalent avidity and receptor availability governs mRNA delivery by antibody-functionalized lipid nanoparticles
10.1021/acs.nanolett.5c06525 · 2026 · External reference
Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines
10.3390/vaccines9040359 · 2021 · External reference
Polymeric nanoparticles for drug delivery
10.1021/acs.chemrev.3c00705 · 2024 · External reference
Polyplexes for gene and nucleic acid delivery: progress and bottlenecks
10.1016/j.ejps.2020.105358 · 2020 · External reference
Divergent delivery and expression kinetics of lipid and polymeric nanoparticles across mRNA modalities
10.1002/advs.202508907 · 2025 · External reference
Precise PBAEs: a highly efficient single-molecularly defined gene-delivery system
10.1002/anie.202422134 · 2025 · External reference
Pneumatically controlled microfluidic synthesis of polymeric nanoparticles for mRNA delivery
10.1039/d5nr05222j · 2026 · External reference
Exosomes and exosome-inspired vesicles for targeted drug delivery
10.3390/pharmaceutics10040218 · 2018 · External reference
Exosomes as therapeutics: The implications of molecular composition and exosomal heterogeneity
10.1016/j.jconrel.2016.02.037 · 2016 · External reference
Engineered exosome-mediated messenger RNA and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering
10.1016/j.jcyt.2023.01.005 · 2023 · External reference
A CAR T-inspiring platform based on antibody-engineered exosomes from antigen-feeding dendritic cells for precise solid tumor therapy
10.1016/j.biomaterials.2022.121424 · 2022 · External reference
Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing
10.1002/jev2.12076 · 2021 · External reference
In vitro and in vivo RNA inhibition by CD9-HuR functionalized exosomes encapsulated with miRNA or CRISPR/dCas9
10.1021/acs.nanolett.8b02689 · 2019 · External reference
Fusogenic lipid nanovesicles as multifunctional immunomodulatory platforms for precision solid tumor therapy
10.1002/smll.202503134 · 2025 · External reference
In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism
10.1002/smll.202304378 · 2024 · External reference
T-cell-targeted fusogenic nanovesicles generate CAR-T cells in vivo for rheumatoid arthritis therapy
10.1186/s40364-026-00905-3 · 2026 · External reference
In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles
10.1016/j.scib.2023.11.055 · 2024 · External reference
Reprogramming human T cell function and specificity with non-viral genome targeting
10.1038/s41586-018-0326-5 · 2018 · External reference
CAR-T cell therapy: current limitations and potential strategies
10.1038/s41408-021-00459-7 · 2021 · External reference
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
10.1038/s41591-018-0201-9 · 2018 · External reference
Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products
10.1186/s12967-022-03729-5 · 2022 · External reference
Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives
10.1186/s12967-016-1047-x · 2016 · External reference
In vivo site-specific engineering to reprogram T cells
10.1038/s41586-026-10235-x · 2026 · External reference
High levels of AAV vector integration into CRISPR-induced DNA breaks
10.1038/s41467-019-12449-2 · 2019 · External reference
In vivo generation of CAR-T cells: Current obstacles, strategic solutions, and clinical translation
10.1016/j.critrevonc.2026.105373 · 2026 · External reference
In vivo generation of CAR T cells: biology, delivery platforms, clinical promise, and translational challenges
10.1016/j.bict.2025.100027 · 2026 · External reference
Improving the safety of cell therapy products by suicide gene transfer
10.3389/fphar.2014.00254 · 2014 · External reference
Advanced strategies to enhance the safety, persistence, and efficacy of CAR-T cells in solid tumors
10.3389/fimmu.2026.1813730 · 2026 · External reference
Progress and prospects: immune responses to viral vectors
10.1038/gt.2009.148 · 2010 · External reference
CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations
10.1053/j.semperi.2018.09.003 · 2018 · External reference
Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors
10.1089/hum.1997.8.10-1207 · 1997 · External reference
Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains
10.3389/fonc.2021.802876 · 2021 · External reference
Charting new frontiers in nanoparticle immunotoxicity: A perspective on current, emerging, and future approaches
10.1016/j.bbrc.2025.152280 · 2025 · External reference
Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy
10.15252/emmm.201708148 · 2017 · External reference
Impact of lipid nanoparticle size on mRNA vaccine immunogenicity
10.1016/j.jconrel.2021.05.021 · 2021 · External reference
Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects
10.1038/s41571-023-00811-9 · 2023 · External reference
Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
10.1136/jitc-2022-005701 · 2023 · External reference
Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy
10.1080/1744666x.2024.2349738 · 2024 · External reference
Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness
10.1038/s41422-023-00789-0 · 2023 · External reference
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
10.1038/nm.3838 · 2015 · External reference
Reducing hinge flexibility of CAR-T cells prolongs survival in vivo with low cytokines release
10.3389/fimmu.2021.724211 · 2021 · External reference
Adeno-associated virus (AAV) as a vector for gene therapy
10.1007/s40259-017-0234-5 · 2017 · External reference
From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy
10.1186/s12967-024-06052-3 · 2025 · External reference
Revolutionizing cancer treatment: the emerging potential and potential challenges of in vivo self-processed CAR cell therapy
10.7150/thno.101941 · 2024 · External reference
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
10.1038/s41419-017-0061-0 · 2018 · External reference
Interleukins in cancer: from biology to therapy
10.1038/s41568-021-00363-z · 2021 · External reference
Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma
10.4049/jimmunol.160.8.3978 · 1998 · External reference
Next generation CAR-T cells to tackle solid tumors
10.1016/j.jconrel.2026.114650 · 2026 · External reference
CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation
10.1016/j.ctrv.2025.103046 · 2025 · External reference
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy
10.1016/j.jhep.2023.01.011 · 2023 · External reference
The tumor microenvironment: A milieu hindering and obstructing antitumor immune responses
10.3389/fimmu.2020.00940 · 2020 · External reference
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
10.1111/imm.12036 · 2013 · External reference
Tumor-associated macrophages in pancreatic ductal adenocarcinoma: origin, polarization, function, and reprogramming
10.3389/fcell.2020.607209 · 2020 · External reference
CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead
10.3389/fimmu.2026.1796675 · 2026 · External reference
Modulating metabolism to improve the therapeutic outcomes of CAR cell therapies: From bench to bedside
10.1016/j.metabol.2025.156375 · 2025 · External reference
Metabolic reprogramming of CAR-T cells: a multi-pronged strategy to conquer the immunosuppressive tumor microenvironment
10.1186/s12964-026-02864-6 · 2026 · External reference
Metabolic regulation of immunity in the tumor microenvironment
10.1016/j.celrep.2025.116463 · 2025 · External reference
Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment
10.1182/bloodadvances.2022008272 · 2023 · External reference
Inhibitory effect of tumor cell-derived lactic acid on human T cells
10.1182/blood-2006-07-035972 · 2007 · External reference
LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells
10.1016/j.cmet.2016.08.011 · 2016 · External reference
Targeting adenosine for cancer immunotherapy
10.1186/s40425-018-0360-8 · 2018 · External reference
Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors
10.1158/0008-5472.can-23-1038 · 2024 · External reference
Targeting ROS-sensing Nrf2 potentiates anti-tumor immunity of intratumoral CD8(+) T and CAR-T cells
10.1016/j.ymthe.2024.08.019 · 2024 · External reference
Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment
10.1172/jci.insight.177141 · 2024 · External reference
Overcoming T cell exhaustion and senescence in CAR T cell therapy for solid tumors
10.1007/s12094-026-04383-9 · 2026 · External reference
Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity
10.1016/j.ccell.2023.04.016 · 2023 · External reference
IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases
10.1038/s41587-023-02060-8 · 2024 · External reference
Circadian engineering of in vivo CAR T cell therapy for precision oncology
10.1038/s41698-026-01464-4 · 2026 · External reference
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial
10.1038/s41408-024-01105-8 · 2024 · External reference
Spatiotemporal dynamics of tumor-CAR T-cell interaction following local administration in solid cancers
10.1371/journal.pcbi.1013117 · 2025 · External reference
Sequential intrathoracic injection and intravenous infusion of BCMA CAR-T cells in a patient with relapsed/refractory primary plasma cell leukemia
10.1007/s12185-025-04064-3 · 2025 · External reference
Mechanism, potential, and concerns of immunotherapy for hepatocellular carcinoma and liver transplantation
10.2174/0118761429310703240823045808 · 2024 · External reference
In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy
10.1080/21645515.2025.2558403 · 2025 · External reference
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy
10.1182/blood.2021012634 · 2022 · External reference
Synthetic cytokine circuits that drive T cells into immune-excluded tumors
10.1126/science.aba1624 · 2022 · External reference
Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism
10.1080/2162402x.2022.2055703 · 2022 · External reference
D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment
10.1016/j.ymthe.2022.01.007 · 2022 · External reference
GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency
10.1038/s41467-024-52666-y · 2024 · External reference
Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation
10.1186/s13046-023-02815-w · 2023 · External reference
Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors
10.21147/j.issn.1000-9604.2023.03.03 · 2023 · External reference
Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors
10.1038/s43018-021-00244-2 · 2021 · External reference
Single-cell mapping of combinatorial target antigens for CAR switches using logic gates
10.1038/s41587-023-01686-y · 2023 · External reference
Amplifying antigen-induced cellular responses with proximity labelling
10.1038/s41586-025-09518-6 · 2025 · External reference
An engineered M13 filamentous nanoparticle as an antigen carrier for a Malignant melanoma immunotherapeutic strategy
10.3390/v16020232 · 2024 · External reference
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
10.1126/science.aan4236 · 2018 · External reference
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
10.1038/s41591-022-01702-9 · 2022 · External reference
Gut microbiota modulation for therapeutic management of various diseases: A new perspective using stem cell therapy
10.2174/1874467215666220222105004 · 2023 · External reference
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
10.1038/s41591-026-04244-6 · 2026 · External reference
Lentiviral particle-mediated generation of in-vivo CAR-T cells for treating refractory B-cell lymphoma
10.1016/j.jcyt.2025.03.432 · 2025 · External reference
1482 In-vivo CAR-T cells produced by specific virus in refractory B cell lymphoma
10.1136/jitc-2024-sitc2024.1482 · 2024 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Updated results from inMMyCAR, the ongoing first-in-human phase 1 study of KLN-1010 in patients with relapsed and refractory multiple myeloma
10.1200/jco.2026.44.16_suppl.7509 · 2026 · External reference
First-in-human dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and initial efficacy of mRNA-LNP MT-302 in vivo CAR therapy in solid tumors
10.1136/jitc-2025-sitc2025.1342 · 2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
First-in-human trial of LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma
2026 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
2025 · External reference
